LAURUSLABS - Laurus Labs Limited Share Price

Pharmaceuticals & Biotechnology

₹819.05-19.55(-2.33%)

Market Closed as of Aug 8, 2025, 15:30 IST

Select time range

Valuation
Market Cap	44.21 kCr
Price/Earnings (Trailing)	86.76
Price/Sales (Trailing)	7.35
EV/EBITDA	34.69
Price/Free Cashflow	-1.12 K
MarketCap/EBT	64.07
Enterprise Value	46.81 kCr

Fundamentals
Revenue (TTM)	6.01 kCr
Rev. Growth (Yr)	32%
Earnings (TTM)	507.34 Cr
Earnings Growth (Yr)	1.18%

Profitability
Operating Margin	11%
EBT Margin	11%
Return on Equity	11.02%
Return on Assets	5.43%
Free Cashflow Yield	-0.09%

Price to Sales Ratio

Latest reported: 7

Revenue (Last 12 mths)

Latest reported: 6 kCr

Net Income (Last 12 mths)

Latest reported: 507 Cr

Growth & Returns
Price Change 1W	-3.6%
Price Change 1M	3.1%
Price Change 6M	27.7%
Price Change 1Y	89.7%
3Y Cumulative Return	14.1%
5Y Cumulative Return	32%
7Y Cumulative Return	37.6%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-681.72 Cr
Cash Flow from Operations (TTM)	601.65 Cr
Cash Flow from Financing (TTM)	39.28 Cr
Cash & Equivalents	99.54 Cr
Free Cash Flow (TTM)	-39.35 Cr
Free Cash Flow/Share (TTM)	-0.73

Balance Sheet
Total Assets	9.34 kCr
Total Liabilities	4.73 kCr
Shareholder Equity	4.6 kCr
Current Assets	4.33 kCr
Current Liabilities	3.54 kCr
Net PPE	3.67 kCr
Inventory	1.94 kCr
Goodwill	246.3 Cr

Capital Structure & Leverage
Debt Ratio	0.29
Debt/Equity	0.59
Interest Coverage	2.16
Interest/Cashflow Ops	3.76

Dividend & Shareholder Returns
Dividend/Share (TTM)	1.2
Dividend Yield	0.15%
Shares Dilution (1Y)	0.10%
Shares Dilution (3Y)	0.50%

Risk & Volatility
Max Drawdown	-33%
Drawdown Prob. (30d, 5Y)	38.46%
Risk Level (5Y)	41.2%

Pros

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Size: Market Cap wise it is among the top 20% companies of india.

Technicals: Bullish SharesGuru indicator.

Balance Sheet: Strong Balance Sheet.

Insider Trading: There's significant insider buying recently.

Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.

Past Returns: In past three years, the stock has provided 14.1% return compared to 11.6% by NIFTY 50.

Profitability: Recent profitability of 8% is a good sign.

Cons

No major cons observed.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	0.15%
Dividend/Share (TTM)	1.2
Shares Dilution (1Y)	0.10%
Earnings/Share (TTM)	9.44

Financial Health
Current Ratio	1.22
Debt/Equity	0.59

Technical Indicators
RSI (14d)	52.87
RSI (5d)	21.75
RSI (21d)	58.83
MACD Signal	Sell
Stochastic Oscillator Signal	Hold
Grufity Signal	Buy
RSI Signal	Hold
RSI5 Signal	Buy
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Sell
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Summary of Latest Earnings Report from Laurus Labs

Summary of Laurus Labs's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated:

Laurus Labs presented a strong outlook during its Q1 FY '26 earnings call, highlighting significant advancements and growth in various segments. Management emphasized a strategic focus on the CDMO business, which achieved impressive revenues of INR 493 crores, driven by mid- to late-stage new chemical entity (NCE) deliveries and expanded manufacturing assets. The company has an active pipeline of over 110 projects, aiming to enhance its integrated offerings.

Key forward-looking points include:

Revenue Growth: The total revenue for Q1 was reported at INR 1,570 crores, reflecting a 31% increase year-on-year. The CDMO segment is projected to contribute 50% to the revenue in the medium term, up from over 30% currently.
Capex Investments: Laurus Labs is investing INR 5,000 crores over the next 4-5 years to expand its manufacturing capabilities, particularly in the microbial fermentation and gene therapy sectors, which are expected to create growth opportunities.
Margin Expansion: Gross margins improved to approximately 59%, with EBITDA margins rising to 25%, up by 10.5 percentage points compared to the previous year. Management expects gross margins to stabilize between 55-60%, supported by the growing share of CDMO.
Capacity Enhancements: Plans include constructing a 400 kiloliter fermentation facility in Vizag, expected to commence operations by the end of 2026, expanding the capacity to address complex molecules, including peptides.
Regulatory and Market Readiness: The company successfully navigated 39 quality audits without critical findings, underpinning the strength of its operational framework and positioning for future growth.

Overall, Laurus Labs maintains a positive outlook, indicating robust demand and a strategic path for sustained growth through investments in advanced capacities and a focus on high-value segments.

Q&A Session

Last updated:

Q1 FY'26 Earnings Conference Call Q&A Summary

Question: Can we expect the current high gross margin of around 59.5% to be maintained as the share of CDMO increases?
Answer: Given our history, we anticipate gross margins to remain between 55% to 60% as CDMO contributions grow, rather than considering it a one-off occurrence.
Question: Do you foresee H2 performance being better than H1 for the CDMO segment this year?
Answer: While we expect growth over last year, the CDMO business can be inconsistent quarter-to-quarter due to clinical program dependencies.
Question: What is the status of Laurus' participation in the upcoming Global Fund tender?
Answer: The tender process typically starts later in the year, and we expect to secure a substantial share based on our previous success.
Question: What progress has been made regarding the food protein fermentation facilities?
Answer: We're constructing a 400 kiloliter capacity in Vizag, with plans for future phases, focusing on various proteins including for food and cosmetics.
Question: What is the market's response to the ImmunoACT CAR-T therapy?
Answer: We're seeing interest from international patients, and partnerships with Big Pharma will further our global presence in this therapy.
Question: Any updates on the viral vector facility for gene therapy?
Answer: We have shifted our facility plans to Hyderabad, expanding to a 6000 square meter site, which will also accommodate capabilities for antibody-drug conjugates.
Question: How do you envision the product mix changing in the next five years?
Answer: We believe CDMO could contribute up to 50% of our revenues as we expand capacity and capabilities across human health, animal health, and crop sciences.
Question: What led to the notable gross margin improvement?
Answer: The gross margin improvements stem from a strong performance in CDMO and product mix shifts rather than a significant change in business structure.
Question: Will there be significant revenue contributions from the crop sciences segment soon?
Answer: We anticipate meaningful revenues in crop sciences next financial year, as current contributions are minimal.
Question: Any insights on the pricing challenges for Laurus Bio?
Answer: The pricing model in Bio is transitioning from monthly fees for reactor usage to per-kilogram billing as products stabilize post-trial phases.

This provides a concise overview of the key questions and answers from the conference call.

Share Holdings

Understand Laurus Labs ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava)	22.99%
NEW WORLD FUND INC	6.49%
ANUKAR PROJECTS PRIVATE LIMITED	3.24%
CHUNDURU VENKATA LAKSHMANA RAO	2.65%
LIFE INSURANCE CORPORATION OF INDIA	2.17%
SBI ARBITRAGE OPPORTUNITIES FUND	1.64%
BARCLAYS WEALTH TRUSTEES INDIA PRIVATE LIMITED	1.61%
AKASH BHANSHALI	1.32%
M/s. Leven Holdings (Represented by its Managing Partner, Mr. Venkata Ravi Kumar Vantaram)	1.24%
SATYANARAYANA CHAVA	0.29%
VENKATA RAVI KUMAR VANTARAM	0.19%
KRISHNAVENI VASIREDDI	0.04%
HYMAVATHI VANTARAM	0.04%
NARASIMHA RAO SURYADEVARA	0.03%
RAMA SURYADEVARA	0.03%
SEKHAR BABU CHUNDURU	0.02%
KAMALA KOMMANA	0.02%
NAGAMANI THOKALA	0.02%
CHAVA NARASIMHA RAO	0.02%
CHANDRAKANTH CHEREDDI	0.01%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Laurus Labs Better than it's peers?

Detailed comparison of Laurus Labs against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	3.81 LCr	55.67 kCr	-4.90%	-8.60%	36.65	6.84	-	-
DIVISLAB	Divi's Lab	1.57 LCr	9.71 kCr	-15.20%	+22.40%	68.19	15.65	-	-
CIPLA	Cipla	1.2 LCr	28.77 kCr	-0.40%	+2.60%	22.25	4.17	-	-
DRREDDY	Dr. Reddy's Lab	1.01 LCr	34.79 kCr	-4.40%	-12.60%	21.6	2.91	-	-
AUROPHARMA	Aurobindo Pharma	60.46 kCr	32.37 kCr	-8.90%	-29.60%	17.85	1.86	-	-

Sector Comparison: LAURUSLABS vs Pharmaceuticals & Biotechnology

Comprehensive comparison against sector averages

Comparative Metrics

LAURUSLABS metrics compared to Pharmaceuticals

Category	LAURUSLABS	Pharmaceuticals
PE	86.76	35.01
PS	7.35	4.96
Growth	18.4 %	8.5 %

Performance Comparison

LAURUSLABS vs Pharmaceuticals (2021 - 2025)

Key Insights

1. LAURUSLABS is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 1.4% in Pharmaceuticals.
3. In last one year, the company has had an above average growth that other Pharmaceuticals companies.

Income Statement for Laurus Labs

Consolidated figures (in Rs. Crores) / View Standalone Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	10.2%	5,554	5,041	6,041	4,936	4,814	2,832
Other Income	196%	75	26	6	15	24	5.92
Total Income	11.1%	5,629	5,067	6,047	4,951	4,837	2,838
Cost of Materials	0.3%	2,429	2,422	2,597	2,269	2,359	1,614
Purchases of stock-in-trade	-5.5%	105	111	156	146	96	16
Employee Expense	12.5%	720	640	581	502	434	345
Finance costs	18.1%	216	183	165	102	68	90
Depreciation and Amortization	11.7%	430	385	324	251	205	187
Other expenses	9.2%	1,301	1,191	1,093	818	671	509
Total Expenses	6.5%	5,145	4,831	4,938	3,867	3,536	2,544
Profit Before exceptional items and Tax	105.5%	484	236	1,109	1,084	1,301	294
Total profit before tax	105.5%	484	236	1,109	1,084	1,301	294
Current tax	69.6%	157	93	290	254	338	54
Deferred tax	-7.9%	-27.02	-24.96	22	-2.8	-20.31	-15.24
Total tax	92.5%	130	68	312	251	317	38
Total profit (loss) for period	121.7%	358	162	793	832	984	255
Other comp. income net of taxes	-20.2%	-3.65	-2.87	-5.63	1.03	5.01	-11.38
Total Comprehensive Income	124.1%	355	159	788	833	989	244
Earnings Per Share, Basic	185.4%	6.65	2.98	14.69	15.42	18.36	4.786
Earnings Per Share, Diluted	186.3%	6.64	2.97	14.64	15.35	18.28	4.786

Description	(%) Q/Q	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024
Revenue From Operations	-8.7%	1,570	1,720	1,415	1,224	1,195	1,440
Other Income	-84.5%	10	59	9.42	4.6	2.51	19
Total Income	-11.2%	1,580	1,779	1,424	1,228	1,197	1,458
Cost of Materials	-4.3%	599	626	653	577	572	591
Purchases of stock-in-trade	76.2%	38	22	35	26	23	41
Employee Expense	20.9%	215	178	189	179	174	161
Finance costs	-7.3%	52	56	58	53	49	50
Depreciation and Amortization	6.4%	117	110	106	108	106	102
Other expenses	-1.2%	335	339	331	318	313	315
Total Expenses	-7.6%	1,356	1,467	1,294	1,205	1,179	1,351
Profit Before exceptional items and Tax	-28.3%	224	312	131	23	18	107
Total profit before tax	-28.3%	224	312	131	23	18	107
Current tax	-25.3%	60	80	35	23	18	43
Deferred tax	173.9%	3.12	-1.87	5.1	-18.09	-12.16	-11.4
Total tax	-19.5%	63	78	40	5.09	6.25	32
Total profit (loss) for period	-30.6%	162	233	93	20	13	75
Other comp. income net of taxes	44.3%	-0.71	-2.07	-1.47	-0.42	0.31	2.26
Total Comprehensive Income	-30.4%	161	231	91	20	13	77
Earnings Per Share, Basic	-39.5%	3.02	4.34	1.71	0.37	0.23	1.4
Earnings Per Share, Diluted	-39.3%	3.02	4.33	1.71	0.37	0.23	1.4

Standalone figures (in Rs. Crores) / View Consolidated Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	8.4%	5,217	4,812	5,773	4,707	4,769	2,797
Other Income	115.2%	100	47	16	22	27	5.81
Total Income	9.4%	5,317	4,860	5,789	4,729	4,796	2,803
Cost of Materials	-1.1%	2,371	2,397	2,516	2,281	2,375	1,605
Purchases of stock-in-trade	-5.5%	105	111	156	146	96	16
Employee Expense	10.3%	609	552	497	445	402	324
Finance costs	20.7%	182	151	146	96	66	88
Depreciation and Amortization	4.1%	359	345	301	235	197	184
Other expenses	8.7%	1,201	1,105	1,083	768	682	501
Total Expenses	5.6%	4,814	4,558	4,738	3,753	3,521	2,499
Profit Before exceptional items and Tax	67.7%	504	301	1,051	975	1,275	304
Total profit before tax	67.7%	504	301	1,051	975	1,275	304
Current tax	75.9%	154	88	271	231	335	53
Deferred tax	-181.3%	-30.42	-10.17	20	-6.1	-16.46	-15.57
Total tax	58.4%	123	78	291	225	319	37
Total profit (loss) for period	70%	380	224	760	750	956	267
Other comp. income net of taxes	0%	-0.76	-0.76	0.79	0.8	5.12	-9.62
Total Comprehensive Income	70.7%	380	223	761	751	961	257
Earnings Per Share, Basic	92.4%	7.06	4.15	14.14	13.97	17.85	56
Earnings Per Share, Diluted	92.1%	7.05	4.15	14.09	13.91	17.77	56

Description	(%) Q/Q	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024
Revenue From Operations	-13.2%	1,433	1,650	1,265	1,185	1,117	1,415
Other Income	-70.4%	22	72	7.12	12	9.3	24
Total Income	-15.6%	1,454	1,722	1,272	1,197	1,126	1,439
Cost of Materials	-5.1%	573	604	629	581	557	580
Purchases of stock-in-trade	76.2%	38	22	35	26	23	41
Employee Expense	20.9%	180	149	162	149	149	138
Finance costs	-10.4%	44	49	48	45	41	42
Depreciation and Amortization	6.9%	94	88	89	91	91	89
Other expenses	-3.1%	315	325	296	293	286	289
Total Expenses	-10.7%	1,243	1,392	1,196	1,139	1,087	1,274
Profit Before exceptional items and Tax	-36.2%	211	330	77	58	39	164
Total profit before tax	-36.2%	211	330	77	58	39	164
Current tax	-27.2%	60	82	33	22	17	46
Deferred tax	-50.1%	-6.16	-3.77	-13.09	-6.32	-7.24	-2.95
Total tax	-31.2%	54	78	19	16	10	43
Total profit (loss) for period	-37.5%	158	252	57	42	29	121
Other comp. income net of taxes	54.4%	-0.19	-1.61	0.28	0.29	0.28	2.91
Total Comprehensive Income	-36.9%	158	250	58	43	29	124
Earnings Per Share, Basic	-47.6%	2.93	4.68	1.06	0.79	0.53	2.25
Earnings Per Share, Diluted	-47.4%	2.93	4.67	1.06	0.79	0.53	2.25

Balance Sheet for Laurus Labs

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	135.7%	100	43	139	67	46	50
Loans, current	65%	0.93	0.8	0.95	0.89	0.97	0.89
Total current financial assets	19.7%	2,158	1,803	1,814	1,632	1,646	1,790
Inventories	-8.1%	1,937	2,107	1,845	1,866	1,685	2,261
Total current assets	5.1%	4,332	4,120	3,835	3,668	3,462	4,173
Property, plant and equipment	7.9%	3,668	3,401	3,446	3,315	3,016	2,835
Capital work-in-progress	-12.1%	458	521	423	444	551	471
Investment property	-100.6%	0	171	178	156	133	134
Goodwill	0%	246	246	246	246	246	246
Non-current investments	84.1%	233	127	124	94	50	30
Total non-current financial assets	60.6%	282	176	171	143	99	93
Total non-current assets	8.5%	5,003	4,610	4,552	4,390	4,199	3,883
Total assets	7%	9,336	8,729	8,387	8,058	7,660	8,056
Borrowings, non-current	-2.3%	646	661	798	653	761	540
Total non-current financial liabilities	-7.2%	708	763	903	784	890	661
Provisions, non-current	8.2%	106	98	93	93	81	81
Total non-current liabilities	6%	1,193	1,126	1,159	1,069	1,179	943
Borrowings, current	-0.6%	2,048	2,060	1,709	1,435	1,211	1,512
Total current financial liabilities	2.1%	3,352	3,283	2,907	2,587	2,119	2,934
Provisions, current	7.7%	29	27	25	22	20	18
Current tax liabilities	51.4%	57	38	36	24	65	113
Total current liabilities	2.3%	3,540	3,459	3,112	2,945	2,432	3,340
Total liabilities	3.2%	4,733	4,585	4,271	4,015	3,612	4,283
Equity share capital	0%	108	108	108	108	108	107
Non controlling interest	1333.3%	130	10	4.62	13	11	9.39
Total equity	11.1%	4,603	4,144	4,116	4,043	4,049	3,773
Total equity and liabilities	7%	9,336	8,729	8,387	8,058	7,660	8,056

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	390%	50	11	43	30	1.42	1.82
Loans, current	0.7%	6.69	6.65	6.6	6.5	6.59	97
Total current financial assets	17%	2,105	1,799	1,699	1,525	1,512	1,637
Inventories	-9.6%	1,739	1,924	1,697	1,734	1,569	2,140
Total current assets	3.7%	4,007	3,865	3,517	3,382	3,171	3,879
Property, plant and equipment	-0.6%	2,763	2,779	2,903	2,897	2,781	2,619
Capital work-in-progress	31.9%	336	255	156	231	357	422
Investment property	-100.9%	0	112	116	93	91	91
Non-current investments	16.6%	740	635	635	432	384	362
Loans, non-current	46.7%	466	318	226	191	64	0
Total non-current financial assets	36.2%	1,358	997	905	668	495	410
Total non-current assets	8.4%	4,580	4,224	4,150	3,939	3,787	3,615
Total assets	6.2%	8,587	8,088	7,667	7,322	6,958	7,495
Borrowings, non-current	5.4%	414	393	491	453	565	470
Total non-current financial liabilities	3.8%	461	444	544	484	594	498
Provisions, non-current	5.5%	97	92	88	89	79	78
Total non-current liabilities	17.5%	861	733	725	680	795	729
Borrowings, current	1.1%	1,910	1,890	1,559	1,319	1,116	1,423
Total current financial liabilities	1.9%	3,041	2,985	2,602	2,329	1,931	2,781
Provisions, current	8%	28	26	24	22	19	17
Current tax liabilities	62.5%	53	33	34	17	44	96
Total current liabilities	2.5%	3,162	3,085	2,736	2,588	2,106	2,979
Total liabilities	5.4%	4,023	3,818	3,460	3,269	2,901	3,708
Equity share capital	0%	108	108	108	108	108	107
Total equity	6.9%	4,564	4,270	4,207	4,053	4,057	3,786
Total equity and liabilities	6.2%	8,587	8,088	7,667	7,322	6,958	7,495

Cash Flow for Laurus Labs

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Change in inventories	44.9%	-82.86	-151.31	82	-174.33	-	-
Depreciation	11.7%	430	385	324	251	-	-
Unrealised forex losses/gains	70.3%	-1.92	-8.82	12	0	-	-
Adjustments for interest income	203.7%	15	5.61	4.56	1.72	-	-
Share-based payments	-10%	10	11	7.48	6.64	-	-
Net Cashflows from Operations	-19.4%	476	590	1,132	1,007	-	-
Interest paid	-19.9%	-209.96	-175	-145.47	-86.19	-	-
Income taxes paid (refund)	31.7%	138	105	285	182	-	-
Other inflows (outflows) of cash	1223.2%	53	4.93	1.65	0	-	-
Net Cashflows From Operating Activities	-9.6%	602	666	994	911	-	-
Cashflows used in obtaining control of subsidiaries	-101.3%	0	80	22	0	-	-
Proceeds from sales of PPE	7515.4%	100	2.3	2.67	0.12	-	-
Purchase of property, plant and equipment	-5.5%	641	678	990	877	-	-
Interest received	11.7%	6.15	5.61	4.56	1.72	-	-
Other inflows (outflows) of cash	-2927.9%	-41.39	-0.4	9.17	-11.74	-	-
Net Cashflows From Investing Activities	17.1%	-681.72	-822.42	-996.06	-914.34	-	-
Proceeds from exercise of stock options	476.9%	10	2.56	7.44	4.31	-	-
Proceeds from borrowings	-33.7%	503	758	468	438	-	-
Repayments of borrowings	45.8%	316	217	247	168	-	-
Payments of lease liabilities	-6.2%	31	33	7.83	73	-	-
Dividends paid	-50.6%	43	86	107	86	-	-
Interest paid	20.2%	209	174	140	85	-	-
Other inflows (outflows) of cash	-	125	0	0	0	-	-
Net Cashflows from Financing Activities	-84.7%	39	250	-26.64	30	-	-
Effect of exchange rate on cash eq.	147%	1.39	0.17	-0.88	-0.13	-	-
Net change in cash and cash eq.	-143.9%	-39.4	93	-29.68	27	-	-

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-70.2%	-35.37	-20.37	-11.2	-8.07	-	-
Change in inventories	66.8%	-41.73	-127.87	119	-155.18	-	-
Depreciation	4.1%	359	345	301	235	-	-
Unrealised forex losses/gains	87.3%	0.01	-6.77	19	7.34	-	-
Share-based payments	-10%	10	11	7.48	6.64	-	-
Net Cashflows from Operations	-25.9%	451	608	1,022	909	-	-
Interest paid	-23.1%	-177.3	-143.81	-126.84	-80.3	-	-
Income taxes paid (refund)	37.1%	134	98	268	166	-	-
Other inflows (outflows) of cash	1048%	46	4.92	1.08	0	-	-
Net Cashflows From Operating Activities	-18.1%	540	659	882	823	-	-
Cashflows used in obtaining control of subsidiaries	-100.4%	0	251	22	43	-	-
Proceeds from sales of PPE	17718.2%	99	1.55	1.23	0.06	-	-
Purchase of property, plant and equipment	3.8%	381	367	742	761	-	-
Cash receipts from repayment of advances and loans made to other parties	-18.3%	99	121	66	0	-	-
Interest received	61.9%	35	22	10	12	-	-
Other inflows (outflows) of cash	-	0.01	0	-0.05	-0.23	-	-
Net Cashflows From Investing Activities	21.8%	-591.65	-756.74	-735.27	-836.61	-	-
Proceeds from exercise of stock options	476.9%	10	2.56	7.44	4.31	-	-
Proceeds from borrowings	-5.1%	525	553	270	377	-	-
Repayments of borrowings	36.5%	244	179	226	155	-	-
Payments of lease liabilities	71.6%	12	7.41	5.79	45	-	-
Dividends paid	-50.6%	43	86	107	86	-	-
Interest paid	23.2%	176	143	123	80	-	-
Net Cashflows from Financing Activities	-58%	59	139	-185.19	15	-	-
Net change in cash and cash eq.	-83.2%	7.73	41	-38.91	1.55	-	-

What does Laurus Labs Limited do?

Pharmaceuticals•Healthcare•Small Cap

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Industry Group:Pharmaceuticals & Biotechnology

Employees:6,007

Website:www.lauruslabs.com

LAURUSLABS - Laurus Labs Limited Share Price

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Risk & Volatility

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Laurus Labs Limited do?